Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$4.12B |
| 2 |
Gilead Sciences
GILD
|
+$379M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$286M |
| 4 |
Amazon
AMZN
|
+$271M |
| 5 |
Meta Platforms (Facebook)
META
|
+$266M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$762M |
| 2 |
SPDR Gold Trust
GLD
|
+$410M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$400M |
| 4 |
QIHU
QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS
QIHU
|
+$227M |
| 5 |
Synchrony
SYF
|
+$195M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 91.35% |
| 2 | Consumer Staples | 2.31% |
| 3 | Technology | 1.26% |
| 4 | Financials | 1.12% |
| 5 | Healthcare | 1.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
PUT
PRA Group
PRAA
$726M
| $3.43M | ﹤0.01% |
99,200
-163,500
| -62% | -$4.82M |
|
2702
ANI Pharmaceuticals
ANIP
$1.69B
| $3.42M | ﹤0.01% |
51,608
+31,789
| +160% | +$1.99M |
|
2703
PUT
Zimmer Biomet
ZBH
$19B
| $3.42M | ﹤0.01% |
27,089
-74,881
| -73% | -$9.25M |
|
|
EQY
2704
CALL
DELISTED
Equity One
EQY
| $3.42M | ﹤0.01% |
111,700
-85,100
| -43% | -$2.69M |
|
|
MFA
2705
MFA Financial
MFA
$896M
| $3.42M | ﹤0.01% |
114,254
+101,378
| +787% | +$3.07M |
|
2706
PUT
iShares TIPS Bond ETF
TIP
$15.1B
| $3.41M | ﹤0.01% |
29,300
+12,100
| +70% | +$1.4M |
|
2707
CALL
Quest Diagnostics
DGX
$27B
| $3.41M | ﹤0.01% |
40,300
+12,200
| +43% | +$1.02M |
|
2708
PUT
Halozyme
HALO
$12.1B
| $3.41M | ﹤0.01% |
282,100
+79,700
| +39% | +$814K |
|
2709
NRG Energy
NRG
$24.1B
| $3.41M | ﹤0.01% |
303,958
+4,925
| +2% | +$64.2K |
|
2710
PUT
Huntington Bancshares
HBAN
$34.1B
| $3.39M | ﹤0.01% |
344,100
-237,400
| -41% | -$2.26M |
|
2711
Hancock Whitney
HWC
$6.02B
| $3.39M | ﹤0.01% |
104,631
| – | – |
|
2712
iShares MSCI China ETF
MCHI
$6.21B
| $3.39M | ﹤0.01% |
69,951
-144,005
| -67% | -$6.63M |
|
2713
PUT
PTC
PTC
$17.2B
| $3.39M | ﹤0.01% |
76,500
-2,600
| -3% | -$108K |
|
2714
PUT
Terex
TEX
$7.38B
| $3.39M | ﹤0.01% |
133,400
-7,900
| -6% | -$184K |
|
|
DNB
2715
PUT
DELISTED
Dun & Bradstreet
DNB
| $3.39M | ﹤0.01% |
24,800
+9,800
| +65% | +$1.31M |
|
2716
Vanguard Morningstar Growth ETF
VUG
$229B
| $3.38M | ﹤0.01% |
180,690
-14,166
| -7% | -$264K |
|
|
VER
2717
DELISTED
VEREIT, Inc.
VER
| $3.38M | ﹤0.01% |
65,236
-3,544
| -5% | -$184K |
|
|
NPTN
2718
PUT
DELISTED
NEOPHOTONICS CORP
NPTN
| $3.38M | ﹤0.01% |
206,800
+192,000
| +1,297% | +$2.7M |
|
2719
Prospect Capital
PSEC
$1.17B
| $3.38M | ﹤0.01% |
416,965
+5,321
| +1% | +$43.9K |
|
2720
CALL
Omega Healthcare
OHI
$14B
| $3.36M | ﹤0.01% |
94,900
+42,700
| +82% | +$1.52M |
|
2721
Steel Dynamics
STLD
$33.8B
| $3.35M | ﹤0.01% |
134,268
| – | – |
|
2722
PUT
AMN Healthcare
AMN
$1.36B
| $3.35M | ﹤0.01% |
105,200
+43,200
| +70% | +$1.64M |
|
|
CEZ
2723
DELISTED
VictoryShares Emerging Market Volatility Wtd ETF
CEZ
| $3.35M | ﹤0.01% |
127,743
-8,711
| -6% | -$231K |
|
2724
Evertec
EVTC
$1.76B
| $3.34M | ﹤0.01% |
199,179
-32,129
| -14% | -$537K |
|
|
PRA
2725
DELISTED
ProAssurance
PRA
| $3.34M | ﹤0.01% |
63,675
+3,040
| +5% | +$161K |
|
Similar funds
Jeff Yass's Q3 2016 Portfolio in Review
As of Q3 2016, Jeff Yass held 9,816 positions worth $207B, up 11% from $187B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jeff Yass's Q3 2016 filing shows 1,347 new, 3,278 increased, 3,435 reduced and 1,488 closed positions. Its largest new stake was Bristol-Myers Squibb: 4,459,411 shares worth $240M. The largest sale was Apple, an estimated $762M.
By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Technology.
- Jeff Yass's largest Q3 2016 buy was Bristol-Myers Squibb: 4,459,411 shares worth $240M.
- Jeff Yass added most to Procter & Gamble in Q3 2016, an estimated $4.12B increase.
- Jeff Yass's biggest Q3 2016 reduction was Apple, cutting an estimated $762M.
- Jeff Yass fully exited QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS in Q3 2016, selling an estimated $227M.
- Jeff Yass's ten largest holdings make up 27% of its $207B portfolio in Q3 2016.
- Jeff Yass opened 1,347 new positions and closed 1,488 in Q3 2016.
- Jeff Yass's portfolio value rose 11% quarter-over-quarter to $207B.
Based on Susquehanna International Group's 13F filing for Q3 2016, filed 14 Nov 2016.